Section: CNS DRUG DESIGN
AND DISCOVERY
Organizing Secretary: Allen B. Reitz, Ph.D.
Johnson & Johnson Pharmaceutical Research and Development
Spring House, USA
PLENARY
LECTURES
|
BACE Inhibitors for the Treatment of Alzheimer’s
Disease
Allen B. Reitz, Ph.D.
Johnson & Johnson
Pharmaceutical Research and Development, Spring House,
USA
|
| INVITED LECTURES
|
Chemical Medicine: The Potential of HDAC Inhibitors
for the Treatment of CNS Disorders
Alan P. Kozikowski
College of Pharmacy, Chicago, USA
|
| Sigma Receptor Modulators
Christopher McCurdy
Department of Medicinal Chemical, School of Pharmacy,
USA
|
| BBB Pentration of Antisense Oligonucleotides
William A. Banks
Department of Internal Medicine, St. Louis University,
School of Medicne, USA
|
| Serotonin/Noradrenaline Reuptake Inhibitors:
As Case History in the Challenges of CNS Drug Discovery
Gavin Whitlock
Pfizer Global Research and Development, Sandwich
Laboratories, USA
|
| Medications Development for the Treatment
of Addictions
Ahmed Elkashef, M.D.
Chief, Clinical Trials Branch, Division of Pharmacotherapies
and Medical Consequences, NIDA, USA
|
| Protein Misfolding and Fibrillogenesis
in Neurodegenerative Diseases: From Mechanistic Studies
to Therapeutic Strategies
Hilal A. Lashuel
Laboratory of Molecular Neurobiology and Neuroproteomics,
Swiss Federal Institute of Technology Lausanne (EPFL),
Switzerland
|
| Conversion of the Mushroom Toxin Muscimol
into THIP (Gaboxadol), a Novel Type of Hypnotic and
Non-Opioid Analgesic
Povl Krogsgaard-Larsen, Ph.D., D.Sc.
The Carlsberg Foundation, Copenhagen, Denmark
|
Glial Glutamate and GABA Transporters as Neuroprotective
Targets
Julianna Kardos
Department of Neurochemistry, Institute of Biomolecular
Chemistry, Chemical Research Center, Hungarian Academy
of Sciences, Budapest, Hungary
|
|
